These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1046 related items for PubMed ID: 17128209

  • 1. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
    Toledo F, Wahl GM.
    Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
    [Abstract] [Full Text] [Related]

  • 2. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F, Wahl GM.
    Int J Biochem Cell Biol; 2007 Dec; 39(7-8):1476-82. PubMed ID: 17499002
    [Abstract] [Full Text] [Related]

  • 3. Reactivation of p53: from peptides to small molecules.
    Brown CJ, Cheok CF, Verma CS, Lane DP.
    Trends Pharmacol Sci; 2011 Jan; 32(1):53-62. PubMed ID: 21145600
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4.
    Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G.
    Cell Death Differ; 2006 Jun; 13(6):927-34. PubMed ID: 16543935
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM.
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [Abstract] [Full Text] [Related]

  • 8. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S, Loureiro JB, Inga A, Reis F, Gomes C, Santos MMM, Saraiva L.
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [Abstract] [Full Text] [Related]

  • 9. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
    Qi DL, Cobrinik D.
    Oncogene; 2017 Mar 30; 36(13):1760-1769. PubMed ID: 27748758
    [Abstract] [Full Text] [Related]

  • 10. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
    Merkel O, Taylor N, Prutsch N, Staber PB, Moriggl R, Turner SD, Kenner L.
    Mutat Res Rev Mutat Res; 2017 Jul 30; 773():1-13. PubMed ID: 28927521
    [Abstract] [Full Text] [Related]

  • 11. The Roles of MDM2 and MDMX in Cancer.
    Karni-Schmidt O, Lokshin M, Prives C.
    Annu Rev Pathol; 2016 May 23; 11():617-44. PubMed ID: 27022975
    [Abstract] [Full Text] [Related]

  • 12. Mdmx and Mdm2: brothers in arms?
    Marine JC, Jochemsen AG.
    Cell Cycle; 2004 Jul 23; 3(7):900-4. PubMed ID: 15254433
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
    Terzian T, Wang Y, Van Pelt CS, Box NF, Travis EL, Lozano G.
    Mol Cell Biol; 2007 Aug 23; 27(15):5479-85. PubMed ID: 17526734
    [Abstract] [Full Text] [Related]

  • 16. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.
    J Hematol Oncol; 2017 Jul 03; 10(1):133. PubMed ID: 28673313
    [Abstract] [Full Text] [Related]

  • 17. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
    Chen D, Kon N, Li M, Zhang W, Qin J, Gu W.
    Cell; 2005 Jul 01; 121(7):1071-83. PubMed ID: 15989956
    [Abstract] [Full Text] [Related]

  • 18. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
    Pellegrino M, Mancini F, Lucà R, Coletti A, Giacchè N, Manni I, Arisi I, Florenzano F, Teveroni E, Buttarelli M, Fici L, Brandi R, Bruno T, Fanciulli M, D'Onofrio M, Piaggio G, Pellicciari R, Pontecorvi A, Marine JC, Macchiarulo A, Moretti F.
    Cancer Res; 2015 Nov 01; 75(21):4560-72. PubMed ID: 26359458
    [Abstract] [Full Text] [Related]

  • 19. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
    Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, Roberts CWM.
    Cancer Res; 2019 May 01; 79(9):2404-2414. PubMed ID: 30755442
    [Abstract] [Full Text] [Related]

  • 20. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
    Leão M, Gomes S, Soares J, Bessa C, Maciel C, Ciribilli Y, Pereira C, Inga A, Saraiva L.
    FEBS J; 2013 Dec 01; 280(24):6498-507. PubMed ID: 24119020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.